Pierre Blanchard, MD

4K posts

Pierre Blanchard, MD banner
Pierre Blanchard, MD

Pierre Blanchard, MD

@PBlanchardMD

Full Prof Radiation Oncology @gustaveroussy @UnivParisSaclay. EiC https://t.co/EihrJjVxi0. Director @SciencesCancer. Adjunct Prof @MDAndersonNews.

Villejuif, France Katılım Mayıs 2015
288 Takip Edilen5.6K Takipçiler
Sabitlenmiş Tweet
Pierre Blanchard, MD
Pierre Blanchard, MD@PBlanchardMD·
It's official! 🍾 I have been appointed Editor in Chief of Radiotherapy & Oncology, aka the Green Journal, @ESTRO_RT's first official journal, starting May 2024. Extremely honored, but also a bit frightened by the task. Big shoes to fill. Will do one step at a time...
Pierre Blanchard, MD tweet media
English
90
25
526
32.6K
Pierre Blanchard, MD retweetledi
Jeff Ryckman
Jeff Ryckman@jryckman3·
🧵 Just published in @TheLancet: TORPEdO – the first phase 3 RCT designed specifically to test whether IMPT (proton beam) improves late function & QoL vs modern IMRT in oropharyngeal SCC. Short answer: It doesn’t. Long answer (with the numbers that matter) 👇
English
7
32
78
19.6K
Pierre Blanchard, MD retweetledi
David Sher
David Sher@DavidSherMD·
Come for the critically important data on protons for oropharyngeal cancer, stay for the beautifully written paper. TORPEdO is out, and it is fascinating and instructive. I will warn you upfront that this is a long thread, but there is a lot here to discuss! thelancet.com/journals/lance…
English
14
39
110
10.4K
Pierre Blanchard, MD retweetledi
OncoAlert
OncoAlert@OncoAlert·
The #OncoAlertTopTweet 🚨DAY ONE #GU26 #APCCC26 🇨🇭 is open to everyone (not just panel members!) and is on April 30-May 2nd in Lugano EARLY REGISTRATION CLOSES February 28, 2026 👉 REGISTER HERE: buff.ly/XpCWPdR Join global experts in advanced #ProstateCancer at the Advanced Prostate Cancer Consensus Conference in Lugano (Palazzo Congressi) for two days of high-level debates addressing real-world clinical questions where evidence is limited, shaping future standards of care published in European Urology while creating opportunities for the next generation of leaders; enjoy 20% off when registering for both APCCC & IPCS 2026 @Silke_Gillessen @AOmlin @fabioturco92 @Prof_IanD @drjefstathiou @Prof_Nick_James @ChrisSweens1 @BertrandTOMBAL @ZilliThomas @neerajaiims @bjartell @PBlanchardMD @BourlonMaite @Albert0Briganti @cdanicas @Ecastromarcos @mdesantis234 @nachoduranm @drlouiseemmett @stefanofanti4 @fontev1 @Nicola_Fossati @marty_gleave @ProfKHerrmann @DrMHofman @BarbaraJereczek @ravikanesvaran @FacsRaja @LoebStacy @quimmateo @DrRanaMcKay @amerseburger @CaPsurvivorship @declangmurphy @DrPaulNguyen @WilliamOhMD @piet_ost @DrSpratticus @cnsternberg @DrYukselUrunPing @nataliagandur @OncoAlert
OncoAlert@OncoAlert

Colleagues at #GU26 ,A reminder that #APCCC26 🇨🇭is coming in 2026 This is a Conference is OPEN TO EVERYONE, not just the Panel members and EARLY REGISTRATION is up until February 28, 2026 👉️ REGISTER HERE: buff.ly/XpCWPdR Only 🔟 days left until the Early Bird deadline (28 February 2026) Enjoy 20% off when registering for both APCCC & IPCS 2026 Awarm invite to the Advanced Prostate Cancer Consensus Conference #APCCC26 in Lugano🇨🇭 Event Details: 📍 Palazzo Congressi, Lugano, Switzerland 🎟️ Register here 🎓 Credits requests: SGU – SSU, SSMO, SRO, SGMN In an era of rapid innovation and expanding treatment options for advanced #ProstateCancer , APCCC provides a vital forum for clinicians and researchers to address complex clinical questions where high-level evidence is limited. Over two days, the world’s leading experts will engage in high-level presentations, debates, and discussions to clarify and conceptualize the current landscape of care, with a focus on areas of controversy or uncertainty. The insights and consensus developed during the meeting are later published in European Urology, helping shape global standards. Creating new opportunities for younger investigators & the next generation of leaders in advanced prostate cancer! @Silke_Gillessen & @AOmlin @fabioturco92 @Prof_IanD @drjefstathiou @Prof_Nick_James @ChrisSweens1 @BertrandTOMBAL @ZilliThomas @neerajaiims @bjartell @PBlanchardMD @BourlonMaite @Albert0Briganti @cdanicas @Ecastromarcos @mdesantis234 @nachoduranm @drlouiseemmett @stefanofanti4 @fontev1 @Nicola_Fossati @marty_gleave @ProfKHerrmann @DrMHofman @BarbaraJereczek @ravikanesvaran @FacsRaja @LoebStacy @quimmateo @DrRanaMcKay @amerseburger @CaPsurvivorship @declangmurphy @DrPaulNguyen @WilliamOhMD @piet_ost @DrSpratticus @cnsternberg @DrYukselUrun Ping @nataliagandur @OncoAlert 🚨

English
0
13
17
1.6K
Pierre Blanchard, MD
Pierre Blanchard, MD@PBlanchardMD·
@DrSpratticus @Xristodouleas Fully agree. Just remember that smaller studies have a higher risk of false positivity. Here a replication in a similar study (eg PCS IX) or meta analysis would strengthen the conclusion. In Wolverine there is 0% heterogeneity across trials, strongly suggesting a true effect.
English
0
0
7
212
Daniel E Spratt
Daniel E Spratt@DrSpratticus·
@Xristodouleas I agree in general if OS was prespecified and it is significant at 95%CI that this should not simply be viewed as a standard phase 2 underpowered for OS. If a priori effect size not known and improves all endpoints and OS it essentially is as close to a phase 3 trial as possible
English
2
0
9
852
John Christodouleas
John Christodouleas@Xristodouleas·
If a trial is designed with a surrogate primary endpoint, like bPFS, but observes a massive benefit across all relevant clinical endpoints, including OS, is it still a “phase 2” trial? What does that even mean when the “intervention” (here SBRT) already has regulatory approval and is widely available? Those are sincere questions.
UroToday.com@urotoday

ARTO Trial: Long-term overall survival analysis from a randomized phase II trial testing the benefit of SBRT addition to abiraterone acetate in oligometastatic #CRPC patients. Presentation by @GiulioFrancoli1 @AOUCareggi. #GU26 written coverage by @RKSayyid @UAUrology > bit.ly/4b2BKa8 @ASCO

English
1
0
7
2.3K
Dr. Andrew Loblaw
Dr. Andrew Loblaw@DrAndrewLoblaw·
Huge! Does anyone know when update is coming out?
Rashid K. Sayyid@RKSayyid

#ASCOGU26 ARTO trial (Ph2, n=157; f/u: 53 mo): Abiraterone +/- SBRT in 1L oligometastatic CRPC Benefit with SBRT: 🔷 bPFS: HR 0.49 (p<0.001) 🔷 rPFS: HR 0.48 (p<0.001) 🔷 OS: HR 0.55 🔷 PCSS: HR 0.37 (p=0.006) 📌63% relative reduction in prostate cancer–specific death with metastasis-directed SBRT. @urotoday

English
1
2
8
1.2K
David Sher
David Sher@DavidSherMD·
This paper is a very important study from @RuehleAlex and Princess Margaret. The authors looked at outcomes following RT for T1-3 N0 glottic larynx squamous cell carcinoma, focusing on the T2 subset, dichotomized into normal versus impaired VC movement. The local failure following treatment of the T2-impaired patients (n=77) was poor: 20% vs. 8% (normal mobility). They also had slightly more regional recurrences (7% vs. 3%). Altogether, the DFS (and OS) for these T2-impaired patients were closer to T3 than T2-normal motion:
David Sher tweet media
Alexander Rühle@RuehleAlex

🔥 Hot off the press: "Prognostic Value of Impaired Vocal Cord Mobility in T2N0 Glottic Cancer Treated With IMRT" ➡️In T2N0 glottic cancer, impaired vocal cord mobility is associated with worse LRF (aHR 3.7) and DFS (aHR 2.7) doi.org/10.1002/lary.7… @PMResearch_UHN @UofTDRO

English
6
8
27
3.7K
Pierre Blanchard, MD
Pierre Blanchard, MD@PBlanchardMD·
@myESMO latest guidelines on advanced #ProstateCancer. For the #radonc community 1. #radiotherapy to the primary remains recommended for low volume mHSPC and an option for high volume mHSPC. 2. Metastasis directed therapy is an option for select oligo mHSPC & mCRPC
Pierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet media
ESMO - Eur. Oncology@myESMO

📣Updated ESMO #ClinicalPracticeGuideline on advanced and metastatic #ProstateCancer: ✅ Substantial advances in castration-sensitive & -resistant prostate cancer ✅ Updated algorithms & recommendations reflecting latest clinical data #ESMOGuidelines 🔗 ow.ly/32vY50Y9T99

English
0
18
41
3.4K
Pierre Blanchard, MD retweetledi
Yungan TAO
Yungan TAO@YG_TAO·
I would like to thank @TheLancet for making GORTEC 2018-01 NIVOPOST-OP trial available with FREE access (upon login) now, enabling broader access to the full dataset and benefiting the head and neck cancer community and beyond.
Yungan TAO@YG_TAO

Excited to share the final publication in The Lancet of our phase 3 GORTEC 2018-01 (NIVOPOST-OP) trial results. We hope these results will support changes in clinical practice and future guideline updates. @PBlanchardMD @DrMLChua @GorphePhilippe thelancet.com/journals/lance…

English
0
4
8
1.5K
Pierre Blanchard, MD
Pierre Blanchard, MD@PBlanchardMD·
6/6 Those investigator initiated studies are a LOT of work, but only them can bring together clinicians and scientists to deliver clinically pertinent trials with high level translational research (more to come on this one and the follow-ups...)
English
0
0
3
167
Pierre Blanchard, MD
Pierre Blanchard, MD@PBlanchardMD·
5/n HPV ctDNA monitoring (digital droplet PCR) measured at baseline and FU, allowed to predict clinical recurrence with a 100% sensitivity, 98% specificity, 83% positive predictive value, and 100% negative predictive value.
English
1
0
4
209
Pierre Blanchard, MD
Pierre Blanchard, MD@PBlanchardMD·
Relevant points here Indeed it seems premature to me to propose the routine use of HPV ctDNA if it does not alter management (de-escalating surveillance) or improve detection of relapses. This is what we test in the randomized SURVEILLE HPV trial (clinicaltrials.gov/study/NCT05582…)
Pierre Blanchard, MD tweet media
David Sher@DavidSherMD

The linked paper is a nice document and summary product, but let's emphasize a few highlights: 1. Statement 16, strong consensus: ctHPVDNA should supplement conventional surveillance tools, rather than reducing or replacing them. Natural corollary: if it is not reducing or replacing surveillance, what is the point? 2. Statement 9, strong consensus: Detectable ctHPVDNA without clinical or radiographic evidence of disease often increases patient distress. 3. Statement 5, strong consensus: Large-scale, prospective randomized controlled trials are necessary to validate ctHPVDNA's role in HPV+ oropharyngeal cancer management. I would change that statement from validate to determine. Validate assumes it has a role today, but as the document states, it doesn't reduce or replace any currently established surveillance tools. There are so many exciting ways that ctHPVDNA may influence care (screening/diagnosis, de-escalation, non-imaging-based surveillance) but these strategies need to be established in prospective randomized trials.

English
1
4
15
2.7K
Pierre Blanchard, MD retweetledi
ESTRO
ESTRO@ESTRO_RT·
🎯 Plan your ICHNO 2026 experience! Early registration ends 17 Dec. 💬 Dr. Yungan Tao explains the theme “Driven by Biology, Centred on the Person” — precision + patient-centred care. 📃: bit.ly/4hwIWhz 👉 Register: bit.ly/3L2CHWn #ICHNO26 #Oncology
English
0
4
12
1.3K
Pierre Blanchard, MD retweetledi
David Sher
David Sher@DavidSherMD·
This provocative cooperative trial is a must-read​ for anyone interested in postoperative radiotherapy for HNSCC. GORTEC’s STEREOPOSTOP was a phase II study of postoperative SBRT following resection of pT1-2 pN0-1 oral cavity or oropharyngeal squamous cell carcinoma. The treatment: 36 Gy in 6 fractions to the primary site, no neck. Extremely gutsy and envelope-pushing for a cooperative group. I love it.
Julian Biau MD, PhD@BiauJulian

@DavidSherMD @PBlanchardMD Link to the final publication : jamanetwork.com/journals/jaman…

English
1
11
19
3.8K
Pierre Blanchard, MD
Pierre Blanchard, MD@PBlanchardMD·
Congrats Aileen for the appointment and Michelle Leech for the incredible decade building tipsRO! Look forward to working together. Cc @RO_GreenJournal
ESTRO@ESTRO_RT

📢 Welcome Aileen Duffton, PhD as the new Editor-in-Chief of tipsRO! ✨Aileen is Lead R&D Radiographer at BWoSCC (Glasgow) and Senior Honorary Lecturer at the University of Glasgow. 🙏We thank Michelle Leech for her outstanding leadership as former EiC! #Radiotherapy #RTT

English
0
0
3
816

Keşfet

@TheLancet @Silke_Gillessen @AOmlin @fabioturco92 @Prof_IanD @drjefstathiou @Prof_Nick_James @ChrisSweens1